Altimmune (ALT) Share-based Compensation (2010 - 2026)

Altimmune (ALT) has 17 years of Share-based Compensation data on file, last reported at $20.6 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 413.08% year-over-year to $20.6 million in Q1 2026; TTM through Mar 2026 was $20.6 million, a 80.61% increase from a year earlier, with the FY2025 full-year figure at $19.7 million, up 12.57% from the prior year.
• Share-based Compensation for Q1 2026 stood at $20.6 million, up from $4.9 million in the prior quarter.
• Over the last five years, Share-based Compensation for ALT reached as high as $20.6 million in Q1 2026 and fell as low as $2000.0 in Q4 2024.
• Historically, Share-based Compensation has averaged $5.2 million across 5 years, with a median of $3.1 million in 2024.
• Across the five-year window, Share-based Compensation sank 99.98% in 2024 and jumped 246950.0% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $1.9 million in 2022, then soared by 435.84% to $10.1 million in 2023, then sank by 99.98% to $2000.0 in 2024, then soared by 246950.0% to $4.9 million in 2025, then surged by 316.92% to $20.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $20.6 million in Q1 2026, $4.9 million in Q4 2025, and $20.2 million in Q3 2025.